Table 2

Results of the multivariate analysis in gold standard patients (training set)

FMFTRAPSCAPSMKD
SymptomsOR (95% CI)SymptomsOR (95% CI)SymptomsOR (95% CI)SymptomsOR (95% CI)
Eastern Mediterranean ethnicity2975 (87 to 22 543)
p<0.0001
Periorbital oedema23 (2.5 to 206)
p<0.0001
Urticarial rash290 (30 to 2757)
p<0.0001
Diarrhoea (always)102 (13 to 812)
p<0.0001
Chest pain68 (7 to 660)
p<0.0001
Duration of episodes >6 days49 (15 to 165)
p=0.0001
Conjunctivitis9.1 (2.2 to 36.6)
p=0.002
Diarrhoea (sometimes/often)18 (5 to 67)
p<0.0001
Abdominal pain166 (7 to 017)
p<0.0001
Migratory rash11 (1.0 to 209)
p=0.05
Neurosensory hearing loss274 (8 to 8944)
p=0.002
Painful lymph nodes5.1 (1.4 to 17.8)
p=0.01
North Mediterranean ethnicity33 (3 to 329)
p=0.0002
Myalgia2.5 (1.0 to 7.1)
p=0.05
Exudative pharyngitis0.004 (0 to 1.0)
p=0.05
Aphthous stomatitis6.3 (1.7 to 23.6)
p=0.001
Duration of episodes <2 days14 (1 to 201)
p=0.05
Relatives affected5.3 (1.7 to 16.9)
p=0.004
Abdominal pain0.04 (0 to 0.15) p<0.0001Age at onset <2 years3.1 (1.0 to 12.2)
p=0.05
Enlarged cervical lymph nodes0.05 (0.005 to 0.4)
p=0.004
Vomiting0.12 (0.03 to 0.54)
p=0.006
Generalised enlargement of lymph nodes or splenomegaly3.9 (1.015.53)
p=0.05
Aphthous stomatitis0.04 (0.004 to 0.5)
p=0.01
Aphthous stomatitis0.07 (0.02 to 0.3)
p<0.001
Chest pain0.1 (0.01 to 0.6)
p=0.01
Urticarial rash0.002 (0.01 to 0.1)
p=0.003
Duration of episodes >6 days0.001 (0.001 to 0.1)
p<0.0001
  • CAPS, cryopyrin-associated periodic syndromes; FMF, familial Mediterranean fever; MKD, mevalonate kinase deficiency; TRAPS, receptor-associated periodic fever syndrome.